GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0006979113 | Thyroid | PTC | response to oxidative stress | 234/5968 | 446/18723 | 6.97e-20 | 9.77e-18 | 234 |
GO:0062197113 | Thyroid | PTC | cellular response to chemical stress | 180/5968 | 337/18723 | 1.36e-16 | 1.16e-14 | 180 |
GO:0032956113 | Thyroid | PTC | regulation of actin cytoskeleton organization | 182/5968 | 358/18723 | 4.64e-14 | 2.79e-12 | 182 |
GO:0032970113 | Thyroid | PTC | regulation of actin filament-based process | 197/5968 | 397/18723 | 8.91e-14 | 4.89e-12 | 197 |
GO:0034599113 | Thyroid | PTC | cellular response to oxidative stress | 151/5968 | 288/18723 | 2.82e-13 | 1.43e-11 | 151 |
GO:0000302113 | Thyroid | PTC | response to reactive oxygen species | 121/5968 | 222/18723 | 2.10e-12 | 9.26e-11 | 121 |
GO:0001701111 | Thyroid | PTC | in utero embryonic development | 175/5968 | 367/18723 | 1.40e-10 | 4.73e-09 | 175 |
GO:0042060112 | Thyroid | PTC | wound healing | 190/5968 | 422/18723 | 7.72e-09 | 1.92e-07 | 190 |
GO:0048732113 | Thyroid | PTC | gland development | 193/5968 | 436/18723 | 2.88e-08 | 6.42e-07 | 193 |
GO:0034614112 | Thyroid | PTC | cellular response to reactive oxygen species | 82/5968 | 155/18723 | 4.32e-08 | 9.27e-07 | 82 |
GO:004677716 | Thyroid | PTC | protein autophosphorylation | 110/5968 | 227/18723 | 1.25e-07 | 2.44e-06 | 110 |
GO:003153220 | Thyroid | PTC | actin cytoskeleton reorganization | 60/5968 | 107/18723 | 1.91e-07 | 3.51e-06 | 60 |
GO:0033674111 | Thyroid | PTC | positive regulation of kinase activity | 201/5968 | 467/18723 | 1.95e-07 | 3.54e-06 | 201 |
GO:000182215 | Thyroid | PTC | kidney development | 133/5968 | 293/18723 | 7.57e-07 | 1.18e-05 | 133 |
GO:000165517 | Thyroid | PTC | urogenital system development | 149/5968 | 338/18723 | 1.41e-06 | 2.01e-05 | 149 |
GO:007200114 | Thyroid | PTC | renal system development | 135/5968 | 302/18723 | 1.76e-06 | 2.43e-05 | 135 |
GO:000110119 | Thyroid | PTC | response to acid chemical | 69/5968 | 135/18723 | 2.55e-06 | 3.34e-05 | 69 |
GO:0048511111 | Thyroid | PTC | rhythmic process | 131/5968 | 298/18723 | 7.06e-06 | 8.33e-05 | 131 |
GO:00480089 | Thyroid | PTC | platelet-derived growth factor receptor signaling pathway | 34/5968 | 56/18723 | 8.20e-06 | 9.42e-05 | 34 |
GO:0031032110 | Thyroid | PTC | actomyosin structure organization | 91/5968 | 196/18723 | 1.35e-05 | 1.45e-04 | 91 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PDGFRA | SNV | Missense_Mutation | | c.2942G>C | p.Arg981Pro | p.R981P | P16234 | protein_coding | deleterious(0.03) | possibly_damaging(0.862) | TCGA-A2-A0T0-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | SD |
PDGFRA | SNV | Missense_Mutation | | c.2953N>A | p.Asp985Asn | p.D985N | P16234 | protein_coding | tolerated(0.27) | benign(0.318) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
PDGFRA | SNV | Missense_Mutation | | c.1711N>A | p.Glu571Lys | p.E571K | P16234 | protein_coding | deleterious(0) | probably_damaging(0.989) | TCGA-AO-A12D-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD |
PDGFRA | SNV | Missense_Mutation | rs763325080 | c.2465N>A | p.Arg822His | p.R822H | P16234 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-AR-A1AV-01 | Breast | breast invasive carcinoma | Male | >=65 | I/II | Chemotherapy | cytoxan | SD |
PDGFRA | SNV | Missense_Mutation | rs767697835 | c.3223N>A | p.Asp1075Asn | p.D1075N | P16234 | protein_coding | deleterious_low_confidence(0.01) | possibly_damaging(0.631) | TCGA-D8-A1XQ-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PDGFRA | SNV | Missense_Mutation | | c.1666G>A | p.Glu556Lys | p.E556K | P16234 | protein_coding | deleterious(0) | probably_damaging(0.993) | TCGA-D8-A27G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PDGFRA | insertion | Frame_Shift_Ins | novel | c.905_906insATCTCCATCTCTTAGAATCTTTCTCCACCATCTCTCCTTTCTAG | p.Met302IlefsTer51 | p.M302Ifs*51 | P16234 | protein_coding | | | TCGA-A2-A0CX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
PDGFRA | insertion | Nonsense_Mutation | novel | c.2875_2876insCCATGTTCAGCTAATTTTTGTATTTTT | p.Lys959delinsThrMetPheSerTerPheLeuTyrPheTer | p.K959delinsTMFS*FLYF* | P16234 | protein_coding | | | TCGA-A7-A0CJ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
PDGFRA | insertion | Frame_Shift_Ins | novel | c.2035_2036insTG | p.Tyr679LeufsTer17 | p.Y679Lfs*17 | P16234 | protein_coding | | | TCGA-A8-A06O-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | letrozole | SD |
PDGFRA | insertion | Nonsense_Mutation | novel | c.2036_2037insGAACAGGAAGT | p.Tyr679Ter | p.Y679* | P16234 | protein_coding | | | TCGA-A8-A06O-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | letrozole | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
5156 | PDGFRA | TYROSINE KINASE, KINASE, CLINICALLY ACTIONABLE, DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE, DRUG RESISTANCE | | Gefitinib | GEFITINIB | 22323597 |
5156 | PDGFRA | TYROSINE KINASE, KINASE, CLINICALLY ACTIONABLE, DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE, DRUG RESISTANCE | | PDGF-BB | | |
5156 | PDGFRA | TYROSINE KINASE, KINASE, CLINICALLY ACTIONABLE, DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE, DRUG RESISTANCE | | CEDIRANIB | CEDIRANIB | |
5156 | PDGFRA | TYROSINE KINASE, KINASE, CLINICALLY ACTIONABLE, DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE, DRUG RESISTANCE | inhibitor | NILOTINIB | NILOTINIB | |
5156 | PDGFRA | TYROSINE KINASE, KINASE, CLINICALLY ACTIONABLE, DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE, DRUG RESISTANCE | inhibitor | MOTESANIB | MOTESANIB | |
5156 | PDGFRA | TYROSINE KINASE, KINASE, CLINICALLY ACTIONABLE, DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE, DRUG RESISTANCE | | DCC-2618 | RIPRETINIB | |
5156 | PDGFRA | TYROSINE KINASE, KINASE, CLINICALLY ACTIONABLE, DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE, DRUG RESISTANCE | inhibitor | 385612180 | | |
5156 | PDGFRA | TYROSINE KINASE, KINASE, CLINICALLY ACTIONABLE, DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE, DRUG RESISTANCE | antibody | RAMUCIRUMAB | RAMUCIRUMAB | |
5156 | PDGFRA | TYROSINE KINASE, KINASE, CLINICALLY ACTIONABLE, DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE, DRUG RESISTANCE | | Pyridine derivative 18 | | |
5156 | PDGFRA | TYROSINE KINASE, KINASE, CLINICALLY ACTIONABLE, DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE, DRUG RESISTANCE | | Paclitaxel | PACLITAXEL | 28514312 |